PMV Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
PMV Pharmaceuticals, Inc. is a clinical-stage precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies designed to target p53 mutations. The p53 tumor suppressor protein is a critical regulator of cell division and genomic stability, and mutations in the TP53 gene are present in approximately half of all human cancers. PMV's unique scientific approach focuses on structurally correcting mutant p53 proteins to restore their wild-type, tumor-suppressing function. The company's lead product candidate is rezatapopt (also known as PC14586), a first-in-class, orally available small molecule structural corrector targeting the p53 Y220C mutation in advanced solid tumors.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the registrational Phase 2 PYNNACLE clinical trial evaluating rezatapopt (formerly PC14586) as a monotherapy at a dose of 2000 mg once-daily in patients with TP53 Y220C advanced solid tumors, with a primary focus on platinum-resistant/refractory ovarian cancer.
Expected impact: Establish clinical proof of concept and secure regulatory approval for a first-in-class p53 reactivator.
Implementing disciplined capital allocation, streamlined manufacturing processes, and targeted reductions in general and administrative expenses to extend the cash runway.
Expected impact: Extend the cash runway to the end of Q2 2027, allowing the company to reach key clinical and regulatory milestones without near-term dilution.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Supports further clinical studies and combination trials involving rezatapopt in solid tumors.
Terms: Not explicitly disclosed.
Co-developing the FoundationOne CDx assay as a companion diagnostic to identify patients with a TP53 Y220C mutation who are likely to respond to rezatapopt.
Terms: Not explicitly disclosed.